Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting
predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical …

The complement system has been considered for a long time as a simple lytic cascade,
aimed to kill bacteria infecting the host organism. Nowadays, this vision has changed and it …

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G)
complement plays a primary role in disease pathogenesis. Herein we report the outcome of …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Studies of complement genetics have changed the landscape of thrombotic
microangiopathies (TMAs), particularly atypical haemolytic uraemic syndrome (aHUS) …

Results Onset of aHUS occurred as frequently during adulthood (58.4%) as during
childhood (41.6%). The percentages of patients who developed the disease were 23 …

Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …

Tremendous advances in our understanding of the thrombotic microangiopathies (TMAs)
have revealed distinct disease mechanisms within this heterogeneous group of diseases. As …

Haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are
diseases characterized by microvascular thrombosis, with consequent thrombocytopaenia …